In this episode, you’ll hear about a new phenotype clinicians have proposed in these guidelines, which is the concept of a non-dilated left ventricular cardiomyopathy phenotype. Dive in to hear more about the updated ESC guidelines on cardiomyopathies with Dr. Juan Pablo Kaski, Consultant Pediatric Cardiologist at Great Ormond Street Hospital (GOSH) and Honorary Associate Professor at the UCL Institute of Cardiovascular Science in London, UK.
First ESC Guidelines on Cardiomyopathies Management
What are the high-risk genotypes and associated predictors of sudden cardiac death? Tune in.

Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Overview
In this episode, you’ll hear about a new phenotype clinicians have proposed in these guidelines, which is the concept of a non-dilated left ventricular cardiomyopathy phenotype. Dive in to hear more about the updated ESC guidelines on cardiomyopathies with Dr. Juan Pablo Kaski, Consultant Pediatric Cardiologist at Great Ormond Street Hospital (GOSH) and Honorary Associate Professor at the UCL Institute of Cardiovascular Science in London, UK.
Title
Share on ReachMD
CloseProgram Chapters
Segment Chapters
Playlist:
Recommended
Phase 3 study results of plozasiran in patients with FCS
Advances in MASLD/MASH: Treating the Liver, the Disease, and the Patient – Chair’s Perspective
Identifying the Great Imitator – Demystifying the Systemic Features of IgG4-Related Disease
IgG4-RD Case Conversations: Retroperitoneal Fibrosis with Refractory Ureteral Involvement
Love Story: Lipid Education for Women’s Heart Health
Level Up Your Skills: Tailoring Management of HF
Effect of Finerenone on NT-proBNP in HFmrEF/HFpEF: FINEARTS-HF Trial
Kidney Risk Stratification in Finerenone Treatment: FINEARTS-HF Trial
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?